2137.HK

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$311M	+998.6%	$-0.45	$-0.45–$-0.45	—	1
2027	$435M	+40.0%	$-0.44	$-0.44–$-0.44	—	1
2028	$2.2B	+397.6%	$-0.35	$-0.35–$-0.35	—	1
2029	$5M	-99.8%	$-0.34	$-0.34–$-0.34	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-20	$-0.11	$-0.16	-47.0%
2026-03-19	$-0.07	$-0.11	-64.6%
2025-08-21	$-0.30	$-0.20	+30.8%
2025-03-21	$-0.24	$-0.33	-35.4%
2024-08-19	$-0.37	$-0.41	-13.0%
2024-03-22	$-0.53	$0.02	+104.3%
2023-08-23	$-0.26	$-0.28	-8.6%
2023-03-24	$-0.19

DCF fair valuemodel estimate

Intrinsic value

$0.86

Price

$0.86

Implied downside

-1%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
2137.HKBrii Biosciences Limited	$0.86	-1.14%	$624M	—
1244.HK3D Medicines Inc.	$2.32	-1.69%	$571M	—
1875.HKBioDlink International Company Limited	$3.73	-1.19%	$2.7B	—
2126.HKJW (Cayman) Therapeutics Co. Ltd	$2.04	+2.01%	$848M	—
2251.HKBeijing Airdoc Technology Co., Ltd.

Brii Biosciences Limited

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.

www.briibio.com

Employees: 80
IPO / List date: Jul 13, 2021
HQ: CN

Held by traders on TradeandTell

No one on the platform currently holds 2137.HK.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 2137.HK as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 2137.HK yet.